This company has been acquired
MRTX Stock Overview
Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Mirati Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$58.70 |
| 52 Week High | US$64.41 |
| 52 Week Low | US$27.30 |
| Beta | 0.77 |
| 1 Month Change | -0.41% |
| 3 Month Change | 6.32% |
| 1 Year Change | 18.92% |
| 3 Year Change | -71.20% |
| 5 Year Change | -5.55% |
| Change since IPO | 590.59% |
Recent News & Updates
Recent updates
We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully
Oct 05
Is Mirati Therapeutics (NASDAQ:MRTX) In A Good Position To Invest In Growth?
Jun 22Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues
May 17We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully
Feb 01Some Analysts Just Cut Their Mirati Therapeutics, Inc. (NASDAQ:MRTX) Estimates
Dec 09We Think Mirati Therapeutics (NASDAQ:MRTX) Can Afford To Drive Business Growth
Oct 08Is There An Opportunity With Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) 30% Undervaluation?
Sep 11Mirati: A Potential Blockbuster Stock, Will Need Patience
Sep 08Mirati jumps 11% as Amgen meets key goal for rival cancer drug
Aug 31Mirati gains as Amgen posts new combination data for rival cancer drug
Aug 08Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues
Aug 08Mirati: Not Looking Good In 2022, But Stronger Prospects In 2-3 Years
Jun 21Shareholder Returns
| MRTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.5% | 0.6% | -0.5% |
| 1Y | 18.9% | -3.8% | 24.3% |
Return vs Industry: MRTX exceeded the US Biotechs industry which returned 6.9% over the past year.
Return vs Market: MRTX matched the US Market which returned 19.4% over the past year.
Price Volatility
| MRTX volatility | |
|---|---|
| MRTX Average Weekly Movement | 1.0% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 18.8% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: MRTX has not had significant price volatility in the past 3 months.
Volatility Over Time: MRTX's weekly volatility has decreased from 10% to 1% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 587 | Chuck Baum | www.mirati.com |
Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation.
Mirati Therapeutics, Inc. Fundamentals Summary
| MRTX fundamental statistics | |
|---|---|
| Market cap | US$4.12b |
| Earnings (TTM) | -US$725.88m |
| Revenue (TTM) | US$38.19m |
107.8x
P/S Ratio-5.7x
P/E RatioIs MRTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRTX income statement (TTM) | |
|---|---|
| Revenue | US$38.19m |
| Cost of Revenue | US$510.48m |
| Gross Profit | -US$472.29m |
| Other Expenses | US$253.59m |
| Earnings | -US$725.88m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -10.35 |
| Gross Margin | -1,236.66% |
| Net Profit Margin | -1,900.65% |
| Debt/Equity Ratio | 0% |
How did MRTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/01/23 21:05 |
| End of Day Share Price | 2024/01/22 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Mirati Therapeutics, Inc. is covered by 28 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Huidong Wang | Barclays |
| George Farmer | BMO Capital Markets Equity Research |
| Jason Matthew Gerberry | BofA Global Research |